Driving small molecule antiviral development for Respiratory Syncytial Virus infection

RSV: Serious Unmet Medical Need
  • RSV is a common and serious cause of respiratory infection in children, the immune-compromised and the elderly
  • The World Health Organization (WHO) estimates that RSV causes 64 million infections and 160,000 infant deaths each year
  • It is the most important respiratory virus, responsible for one-fifth of all lower respiratory tract infections worldwide
  • There are no effective treatments or vaccines available against RSV

Leading the Way: RV521

  • An RSV fusion (F) protein inhibitor
  • Best-in-class drug to treat RSV infections
  • Completed Phase 1 studies with antiviral exposures achieved
  • Completed RSV challenge model with high potency against both viral load and symptoms
  • Excellent safety profile
  • Entering an international multicentre Phase 2 paediatric trial

Meet the Team...
Latest News
ReViral Appoints Alex C. Sapir as Chief Executive Officer
  • Proven leader with extensive corporate strategy experience in the biotechnology sector
  • Dr. Eddy Littler to remain as Chief Operating...
ReViral to Present Data Showing Absence of Clinical Resistance in Volunteers Infected with RSV then Treated with Sisunatovir (RV521)

Highly encouraging resistance profile of Company’s lead drug candidate to be presented at the 32nd International Conference on Antiviral Research...

ReViral Announces Grant of Key US Composition of Matter Patent For Their Respiratory Syncytial Virus inhibitor programme

• Patent claims RSV fusion protein inhibitors as medicines including lead pipeline candidate, RV521; patent nominally expires in 2035 (unextended)
• The...

Contact us...